As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development of more effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. This will be accomplished through application of this methodology to the discovery and characterization of new drug-like small molecule therapeutics disrupting interactions relevant to anti-cancer therapy. Improved strategies for developing pharmaceuticals based on inhibitors of protein-protein interactions would be beneficial in order to overcome the limitations of the majority of currently druggable targets to those involving ligand-receptor and enzyme-substrate interactions. We will focus our efforts on the Cyclin Dependent Kinase substrate recruitment site as a validated antitumor drug target. Through this site, the opportunity exists to develop potent and selective inhibitors that are specific to the cell cycle CDKs. Such compounds possessing appropriate drug-like characteristics will potentially be different mechanistically from ATP competitive CDK inhibitors, targeting tumor cells selectively and thereby addressing issues with agents currently being developed.
The major goal of this project is extend and further validate a unique drug discovery strategy for blocking the association of protein-protein complexes and to apply this methodology to discover new drug-like small molecule therapeutics disrupting such interactions relevant to anti-cancer therapy. We will focus on the Cyclin Dependent Kinase substrate recruitment site, through which the opportunity exists to develop potent and selective inhibitors that are specific to the cell cycle CDKs. Such compounds possessing appropriate drug-like characteristics will be different mechanistically from ATP competitive CDK inhibitors, targeting tumor cells selectively and addressing issues with agents currently being developed.
|Grigoroudis, Asterios I; Kontopidis, George (2016) Preparation of CDK/Cyclin Inhibitor Complexes for Structural Determination. Methods Mol Biol 1336:29-45|
|Premnath, Padmavathy Nandha; Craig, Sandra N; Liu, Shu et al. (2016) Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy. Bioorg Med Chem Lett 26:3754-60|
|Grigoroudis, Asterios I; McInnes, Campbell; Premnath, Padmavathy Nandha et al. (2015) Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones. Protein Expr Purif 113:8-16|
|Nandha Premnath, Padmavathy; Craig, Sandra; McInnes, Campbell (2015) Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors. J Vis Exp :e52441|
|Premnath, Padmavathy Nandha; Craig, Sandra N; Liu, Shu et al. (2015) Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem 58:433-42|
|Premnath, Padmavathy Nandha; Liu, Shu; Perkins, Tracy et al. (2014) Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors. Bioorg Med Chem 22:616-22|
|Liu, Shu; Premnath, Padmavathy Nandha; Bolger, Joshua K et al. (2013) Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly. J Med Chem 56:1573-82|
|Liu, Shu; Bolger, Joshua K; Kirkland, Lindsay O et al. (2010) Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol 5:1169-82|